CN102579482A - Medicinal composition for treating allergic rhinitis - Google Patents
Medicinal composition for treating allergic rhinitis Download PDFInfo
- Publication number
- CN102579482A CN102579482A CN2012100901795A CN201210090179A CN102579482A CN 102579482 A CN102579482 A CN 102579482A CN 2012100901795 A CN2012100901795 A CN 2012100901795A CN 201210090179 A CN201210090179 A CN 201210090179A CN 102579482 A CN102579482 A CN 102579482A
- Authority
- CN
- China
- Prior art keywords
- allergic rhinitis
- gram
- montmorillonitum
- treating allergic
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a medicinal composition for treating allergic rhinitis. The medicinal composition is characterized by containing montmorillonite and sodium hyaluronate. When montmorillonite and sodium hyaluronate are combined to be used for treating allergic rhinitis through nasal administration, nasal cavities of patients are not dried, lumps are not formed in nostrils and high patient compliance is ensured; and montmorillonite is not dried, so the effective time of the medicinal composition is long and the medicinal composition is administrated for a few times.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, be specifically related to a kind of pharmaceutical composition of treating allergic rhinitis, belong to medical technical field.
Background technology
Allergic rhinitis are claimed allergic rhinitis again, are a kind of commonly encountered diseases at hals,Nasen und Ohrenheilkunde, are to cause in the body nasal mucosa chronic inflammatory reaction property disease that changes and cause by sensitinogen, and at sickness rate in recent years ascendant trend are year by year arranged.The main clinical performance has nasal obstruction, rhinorrhea, rhinocnesmus, sneeze, and the olfactory function obstacle etc.Primary disease can have a strong impact on patient's quality of life, and causes patient's work or school grade to descend, and increases patient's financial burden, and the social environment incompatibility is influenced doings, can cause hypoevolutism the child especially.Allergic rhinitis often is associated with asthma and conjunctivitis etc., thereby is serious chronic respiratory tract disease, is considered to one of risk factor of asthma morbidity simultaneously.Therefore, allergic rhinitis are not only medical problem, and are social problems, have become the global health problem that needs to be resolved hurrily, are badly in need of furtheing investigate.
The clinical treatment method of allergic rhinitis is a lot, mainly by avoiding contacting allergen, Drug therapy, immunization therapy.The sensitizer of allergic rhinitis is the imbedibility sensitizer mostly, generally is difficult to avoid contact, so Drug therapy and immunization therapy particular importance.
Classical Drug therapy can fall into 5 types, and comprises antihistaminic, Decongestant, anticholinergic agent, glucocorticoid and mastocyte membrane stabilizer etc.That the medicine-feeding way of these medicines has is oral, the people is inhaled in collunarium and atomizing etc. several kinds.In the treatment of allergic rhinitis, be first-selection, and mostly Decongestant, anticholinergic agent and mastocyte membrane stabilizer are adjuvant drug when treatment of allergic rhinitis with glucocorticoid and antihistamine drug.
Glucocorticoid is a line medicine of treatment of allergic rhinitis, through transcribing of regulator gene, increases transcribing and reducing the inflammatory gene transcription and bring into play antiinflammatory action of anti-inflammation gene.Because nose plays a role at molecular level with corticosteroid medication, needs the regular hour, so the onset time that medicine usually need be certain, want at the soonest about 3 hours.Aspect safety, particularly prolonged application is the problem of clinical special concern to the inhibitory action of hypothalamus one hypophysis one hypothalamic pituitary adrenal axis with to the influence of upgrowth and development of children.Because 3-11 year, growth of children was mainly by hormonal system, particularly growth hormone is regulated, and exogenous corticosteroid can influence hypothalamus pulsatile secretion growth hormone, can produce the medicine influence to children growth.
The history in existing more than 60 year of antihistaminic treatment of allergic rhinitis; There are some researches show; The antihistaminic treatment only has 33%-50% pollinosis patient transference cure, and curative effect is low, and central inhibitory action is in various degree arranged; Be easy to generate after taking sleepy, so should not take to being engaged in motor vehicle driving, work high above the ground, operation of precision tool person.
Decongestant (oral medicine or local application) directly acts on alpha-adrenergic receptor, makes vasoconstriction and the blood supply that reduces nasal mucosa.Decongestant can be alleviated nasal congestion effectively, but invalid to other symptoms of allergic rhinitis.The part can cause hyperemia of knock-on property or medicamentous rhinitis with Decongestant such as improper use.
With the before existing bibliographical information of smectite in treatment allergic rhinitis.Clinical trial finds that its weak point is: simple Montmorillonitum preparation nasal-cavity administration; Can improve symptoms such as sneeze that allergic rhinitis causes, watery nasal discharge, nasal obstruction, rhinocnesmus immediately, but the patient is generally reflected dry nasal cavity, makes us unhappy; After the very fast drying of Montmorillonitum; Form block in the nostril with nasal secretion, be bonded on the vibrissa, stop up the nostril and be difficult for removing; Effective time is short, needs multiple dosing.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition of treating allergic rhinitis, its instant effect, nasal cavity is moist, and the medication number of times is few, has no side effect.
The objective of the invention is to realize like this: a kind of pharmaceutical composition of treating allergic rhinitis, contain following effective ingredient: Montmorillonitum and hyaluronic acid sodium.
A kind of pharmaceutical composition of treating allergic rhinitis that the present invention is above-mentioned, per 100 milliliters or per 100 grams contain Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram in the compositionss, and remaining is pharmaceutic adjuvant and water.
A kind of pharmaceutical composition of treating allergic rhinitis that the present invention is above-mentioned, per 100 milliliters or per 100 grams contain Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram in the compositionss, and remaining is Ph value buffer agent, osmotic pressure regulator, antiseptic and water.
A kind of pharmaceutical composition of treating allergic rhinitis that the present invention is above-mentioned; Per 100 milliliters or per 100 grams contain in the compositionss Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram, glycerol 0-3g, sodium chloride 0-0.9g, phosphoric acid buffer to or borate buffer to or hydrochloric acid adjusting Ph value 5-7.5, remaining is antiseptic and water.
A kind of pharmaceutical composition of treating allergic rhinitis that the present invention is above-mentioned is nasal-cavity administrations, and the dosage form of clinical practice is nasal drop, spray or ointment.Splash into, spray into or be applied to nasal cavity during use.Also can use spray spray into simultaneously nasal cavity be sprayed onto pharyngeal.Also available cotton rod dips in gets a little compositions, is applied to the nasal cavity and the bridge of the nose thereof and wing of nose place, and use 2-4 every day, also can reduce access times according to symptom, and using dosage need not particular restriction.
The method for preparing of nasal drop, spray or ointment that the present invention is above-mentioned is a method for preparing commonly used in the pharmaceutics, comprises sterilization, regulates osmotic pressure and adds antiseptic.
Montmorillonitum in the pharmaceutical composition of the present invention can adsorb anaphylactogen and inflammatory mediator thereof behind the entering nasal cavity, improves the symptom of allergic rhinitis immediately; Hyaluronic acid sodium in the compositions has the title of " molecule sponge "; Can absorb and keep himself weight 500-1000 water doubly; And generation gel; Can form one deck hydration shell rapidly after getting into nasal cavity, keep moisture-keeping function, overcome simple use Montmorillonitum and be easy to short, patient's side effects of drying, action time; Hyaluronic acid sodium can promote monocytic pathology phagocytosis, prevents that inflammation from oozing out, and has directly promoted growth, differentiation, reconstruction and the structure repair of cell.Find that through clinical trial the two combination nasal-cavity administration is used for treatment of allergic rhinitis, patient's nasal cavity is moist, and the nostril does not have block and forms, and patient's compliance is good; Montmorillonitum is moist, and effective time is long, and administration number of times is few.
The specific embodiment
The objective of the invention is to realize like this: a kind of pharmaceutical composition of treating allergic rhinitis, contain following effective ingredient: Montmorillonitum and hyaluronic acid sodium.
A kind of pharmaceutical composition of treating allergic rhinitis that the present invention is above-mentioned, per 100 milliliters or per 100 grams contain Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram in the compositionss, and remaining is pharmaceutic adjuvant and water.
A kind of pharmaceutical composition of treating allergic rhinitis that the present invention is above-mentioned, per 100 milliliters or per 100 grams contain Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram in the compositionss, and remaining is Ph value buffer agent, osmotic pressure regulator, antiseptic and water.
A kind of pharmaceutical composition of treating allergic rhinitis that the present invention is above-mentioned; Per 100 milliliters or per 100 grams contain in the compositionss Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram, glycerol 0-3g, disodiumedetate 0.01-0.5g, phosphoric acid buffer to or borate buffer to or hydrochloric acid adjusting Ph value 5-7.5, remaining is a water.
A kind of pharmaceutical composition of treating allergic rhinitis that the present invention is above-mentioned is nasal-cavity administrations, and the dosage form of clinical practice is nasal drop, spray or ointment.Splash into, spray into or be applied to nasal cavity during use.Also can use spray spray into simultaneously nasal cavity be sprayed onto pharyngeal.Also available cotton rod dips in gets a little compositions, is applied to the nasal cavity and the bridge of the nose thereof and wing of nose place, and use 2-4 every day, also can reduce access times according to symptom, and using dosage need not particular restriction.
The method for preparing of nasal drop, spray or ointment that the present invention is above-mentioned is a method for preparing commonly used in the pharmaceutics, comprises sterilization, regulates osmotic pressure and adds antiseptic.
Further specify the present invention below for example.
Embodiment 1
Take by weighing Montmorillonitum Montmorillonitum 3 grams, hyaluronic acid sodium 0.05 gram, add water to 100ml, stir, become the uniform liquid of Montmorillonitum fineness of the particles, divide to be filled to dropper, behind cobalt 60 radiation sterilizations, promptly get nasal drop less than 20 μ m with milling treatment of colloid.
Embodiment 2
Take by weighing Montmorillonitum montmorillonite 20 gram, hyaluronic acid sodium 0.5 gram, ethyl hydroxybenzoate 3g adds water to 100ml, stirs, and hyaluronic acid sodium is dissolved fully, and packing promptly gets nasal drop.
Embodiment 3
Take by weighing Montmorillonitum 5 grams, hyaluronic acid sodium 0.1 gram, ethyl hydroxybenzoate 3g adds water to 100ml, stirs, and hyaluronic acid sodium is dissolved fully, after boiling sterilization in 20 minutes, divides to be filled to spray nose device, promptly gets spray.
Embodiment 4
Take by weighing Montmorillonitum 15 grams, hyaluronic acid sodium 0.3 gram, add an amount of water, stir, hyaluronic acid sodium is dissolved fully; Add glycerol 1 gram, disodiumedetate 0.01 gram, stir, phosphate buffer is regulated Ph value to 5, adds water to 100 milliliters; Sterilization, packing promptly gets spray.
Embodiment 5
Take by weighing montmorillonite 2 0g, hyaluronic acid sodium 0.08g; Chondroitin sulfate 3g, bromo geramine 0.005g, disodiumedetate 0.5g adds water to 100ml; Dilute hydrochloric acid is regulated Ph value to 7.5; Become the uniform liquid of Montmorillonitum fineness of the particles with milling treatment of colloid,, promptly get ointment through cobalt 60 radiation sterilizations less than 10 μ m.
Embodiment 6
Take by weighing Montmorillonitum 10g, hyaluronic acid sodium 0.2g, phenylmercuric acetate 0.002g, glycerol 3g, that disodiumedetate 0.3g adds water is an amount of, stirs, and borate buffer solution is regulated Ph value to 6.8, adds water to 100ml, and after the sterilization, branch is filled to dropper, promptly gets nasal drop.
Embodiment 7
Take by weighing Montmorillonitum 9 grams, hyaluronic acid sodium 0.4 gram, ethyl hydroxybenzoate 3g, glycerol 0.5g, disodiumedetate 0.1g; Add water to 100 grams, stir, phosphate buffer is regulated Ph value to 5.5, and sodium chloride is transferred osmotic pressure to 1; Divide to be filled to dropper,, promptly get nasal drop through cobalt 60 radiation sterilizations.
Claims (4)
1. a pharmaceutical composition of treating allergic rhinitis is characterized in that containing effective ingredient: Montmorillonitum and hyaluronic acid sodium.
2. according to a kind of pharmaceutical composition of treating allergic rhinitis of claim 1, remaining is pharmaceutic adjuvant and water to it is characterized in that containing in per 100 milliliters or the per 100 gram compositionss Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram.
3. according to a kind of pharmaceutical composition of treating allergic rhinitis of claim 1 or claim 2, remaining is Ph value buffer agent, osmotic pressure regulator, antiseptic and water to it is characterized in that containing in per 100 milliliters or the per 100 gram compositionss Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram.
4. according to a kind of pharmaceutical composition of treating allergic rhinitis of claim 1 or claim 2 or claim 3; It is characterized in that per 100 milliliters or per 100 grams contain in the compositionss Montmorillonitum 3-20 gram, hyaluronic acid sodium 0.05-0.5 gram, glycerol 0-3g, sodium chloride 0-0.9g, phosphoric acid buffer to or borate buffer to or hydrochloric acid adjusting Ph value 5-7.5, remaining is antiseptic and water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100901795A CN102579482A (en) | 2012-03-30 | 2012-03-30 | Medicinal composition for treating allergic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100901795A CN102579482A (en) | 2012-03-30 | 2012-03-30 | Medicinal composition for treating allergic rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579482A true CN102579482A (en) | 2012-07-18 |
Family
ID=46469087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100901795A Pending CN102579482A (en) | 2012-03-30 | 2012-03-30 | Medicinal composition for treating allergic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579482A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579334A (en) * | 2012-03-31 | 2012-07-18 | 济南康众医药科技开发有限公司 | Nasal drops containing sodium hyaluronate and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10360425A1 (en) * | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications |
| CN101766647A (en) * | 2009-01-06 | 2010-07-07 | 郭进军 | Purpose of montmorillonite in treating allergic rhinitis and skin allergy |
-
2012
- 2012-03-30 CN CN2012100901795A patent/CN102579482A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10360425A1 (en) * | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications |
| CN101766647A (en) * | 2009-01-06 | 2010-07-07 | 郭进军 | Purpose of montmorillonite in treating allergic rhinitis and skin allergy |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579334A (en) * | 2012-03-31 | 2012-07-18 | 济南康众医药科技开发有限公司 | Nasal drops containing sodium hyaluronate and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2369516T3 (en) | USE OF MOMETASONE FUROATE TO TREAT RESPIRATORY AND PULMONARY ROUTE DISEASES. | |
| JP5683719B2 (en) | Bepotastine composition | |
| MX2011000590A (en) | Intranasal compositions comprising a decongestant and a corticosteroid. | |
| MX2007001561A (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases. | |
| JP5773437B2 (en) | Recombinant human CC10 and compositions thereof for use in the treatment of rhinitis | |
| TW200524615A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| US20220047627A1 (en) | Non-infective nasal symptom management compositions and methods | |
| CA2811345C (en) | Compound composition for inhalation used for treating asthma | |
| JP2019507786A (en) | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| BRPI0313611B1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALLERGIC RHINITE AND / OR ALLERGIC CONJUNTIVITE FOR MUCOSA APPLICATION AND USE OF DITA COMPOSITION | |
| CN107362141A (en) | A kind of Anefrin Nasal Spray and preparation method thereof | |
| US20210386748A1 (en) | Non-infective nasal symptom management compositions and methods | |
| US11701426B2 (en) | Non-infective nasal symptom management compositions and methods | |
| CN101564396A (en) | Two chamber type nose spraying agent for treating allergic rhinitis | |
| CN102579482A (en) | Medicinal composition for treating allergic rhinitis | |
| US20200121696A1 (en) | Non-infective nasal symptom management compositions and methods | |
| CN102600204A (en) | Medicinal composition for treating allergic rhinitis | |
| TWI495466B (en) | Inhaled combination product for asthma | |
| Gandhi et al. | Medication conveyance through nose: Factors affecting and novel applications | |
| Wang et al. | Chinese expert recommendation on transnasal corticosteroid nebulization for the treatment of chronic rhinosinusitis 2021 | |
| IT201900013524A1 (en) | New formulations of amisulpride | |
| CN117695224A (en) | Nasal spray, preparation method and application thereof | |
| JP2023525662A (en) | Medicines and nasal sprays containing trehalose or derivatives of trehalose | |
| CN102579481A (en) | Medicinal composition for treating catarrh symptom | |
| CN109091667A (en) | Purposes and combinations thereof of the human urokinase-type peptidase in preparation treatment migraine remedy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120718 |